Suppr超能文献

单次玻璃体内注射贝伐单抗对增殖性糖尿病视网膜病变患者视力及玻璃体视网膜手术进程的影响

Outcome of a Single Intravitreal Bevacizumab Injection on the Visual Acuity and Course of Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy.

作者信息

Elwan Mohamed M, Ghanem Asaad A, Abousamra Waleed A

机构信息

Mansoura Ophthalmic Center, Mansoura University , Masnoura , Egypt.

出版信息

Curr Eye Res. 2013 Sep 27. doi: 10.3109/02713683.2013.833247.

Abstract

Abstract Purpose: To evaluate the effect of a single intravitreal 1.25 mg/0.05 ml bevacizumab (IVB) (Avastin, Genentech) injection on the visual outcome and both intraoperative and postoperative course of pars plana vitrectomy (PPV) in proliferative diabetic retinopathy. Study Design: Prospective case-control interventional comparative study. Methods: One hundred patients (100 eyes) were divided into two groups: Group I had undergone PPV with preoperactive IVB (50 patients), and Group II had undergone PPV without IVB (50 patients). Best corrected visual acuity (BCVA), intraoperative and postoperative complications were compared between both groups. Patients were followed-up for one year. Results: After one year, there was a highly statistically significant difference in the mean BCVA, as it was (0.146 ± 0.103) in Group I and 0.069 ± 0.049 in Group II with (p < 0.001), while mean bleeding frequency in Group I was 0.7 ± 0.78 times/case with range between 0 and 2 bleeding attacks/case and mean bleeding frequency in Group II was 3.12 ± 1.31times/case with range between 3 and 6 bleeding attacks/case and the difference was statistically significant as (p < 0.001). Diathermy was used in Group I in 15 patients only with mean frequency of 0.3 ± 0.46 times/case with range between 0 and 1 attack/case; while diathermy was used in all cases in Group II with mean frequency of 2.4 ± 1.06 times/case with range between 1 to 4 times/case and this difference was also statistically significant as p < 0.001. Postoperative vitreous hemorrhage developed in 3 eyes (6%) in Group I and 15 eyes (30%) in Group II and this difference was statistically significant (p < 0.003). All the other intraoperative and postoperative complications were reduced in Group I, but with no statistically significant difference between both groups. Conclusions: The use of intravitreal bevacizumab before pars plana vitrectomy is beneficial in improving visual outcome, minimizing the incidence of intraoperative bleeding and reducing the need for intraoperative diathermy.

摘要

摘要 目的:评估玻璃体内单次注射1.25毫克/0.05毫升贝伐单抗(IVB)(阿瓦斯汀,基因泰克公司)对增殖性糖尿病视网膜病变患者的视力预后以及玻璃体切割术(PPV)术中及术后过程的影响。研究设计:前瞻性病例对照干预性比较研究。方法:100例患者(100只眼)分为两组:第一组50例患者在PPV术前接受了IVB注射,第二组50例患者未接受IVB注射直接进行PPV。比较两组患者的最佳矫正视力(BCVA)、术中及术后并发症情况。对患者进行为期一年的随访。结果:一年后,两组患者的平均BCVA存在高度统计学差异,第一组为(0.146±0.103),第二组为0.069±0.049(p<0.001);第一组平均出血频率为0.7±0.78次/例,每例出血发作次数在0至2次之间,第二组平均出血频率为3.12±1.31次/例,每例出血发作次数在3至6次之间,差异具有统计学意义(p<0.001)。第一组仅15例患者使用了透热疗法,平均频率为0.3±0.46次/例,每例发作次数在0至1次之间;而第二组所有病例均使用了透热疗法,平均频率为2.4±1.06次/例,每例发作次数在1至4次之间,此差异也具有统计学意义(p<0.001)。第一组3只眼(6%)发生了术后玻璃体积血,第二组15只眼(30%)发生了术后玻璃体积血,差异具有统计学意义(p<0.003)。第一组所有其他术中及术后并发症均有所减少,但两组之间无统计学差异。结论:在玻璃体切割术前使用玻璃体内贝伐单抗有助于改善视力预后,降低术中出血发生率,并减少术中透热疗法的使用需求。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验